RESUMEN
With new drugs being introduced to treat asthma it is timely to review criteria that can be used to assess efficacy in clinical trials. Anti-asthma drugs are classified into symptoms-modifying, symptom preventers and disease modifying agents. Attention is drawn to the types of experimental evidence required in preclinical studies to support further clinical development of a new therapy. Clinical trials demand careful selection of patients to maximise the strength of the efficacy signal according to the type of trial being designed. While provocation tests are useful in suggesting efficacy, negative tests do not necessarily indicate lack of anti-asthma activity. Therapeutic trial designs need to take account of duration of treatment, dose-response relationships and confirmatory trials. Outcome measures include symptoms, lung function, reduction in concomitant medication, exacerbations, quality of life and measures of inflammation. Interpretation of results need to include the clinical relevance of any changes as well as statistical significance. Special consideration needs to be given to the evaluation of drugs for acute severe asthma, asthma in children and older people, co-morbidity such as rhinitis, and inhaler devices. As with all drugs introduced into practice, careful attention needs to be paid to both short- and long-term safety.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Ensayos Clínicos como Asunto/métodos , Enfermedad Aguda , Administración por Inhalación , Adulto , Anciano , Asma/diagnóstico , Niño , Evaluación Preclínica de Medicamentos/métodos , Humanos , Nebulizadores y Vaporizadores , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate the efficacy of homoeopathic immunotherapy on lung function and respiratory symptoms in asthmatic people allergic to house dust mite. DESIGN: Double blind randomised controlled trial. SETTING: 38 general practices in Hampshire and Dorset. PARTICIPANTS: 242 people with asthma and positive results to skin prick test for house dust mite; 202 completed clinic based assessments, and 186 completed diary based assessments. INTERVENTION: After a four week baseline assessment, participants were randomised to receive oral homoeopathic immunotherapy or placebo and then assessed over 16 weeks with three clinic visits and diary assessments every other week. OUTCOME MEASURE: Clinic based assessments: forced expiratory volume in one second (FEV(1)), quality of life, and mood. DIARY BASED ASSESSMENTS: morning and evening peak expiratory flow, visual analogue scale of severity of asthma, quality of life, and daily mood. RESULTS: There was no difference in most outcomes between placebo and homoeopathic immunotherapy. There was a different pattern of change over the trial for three of the diary assessments: morning peak expiratory flow (P=0.025), visual analogue scale (P=0.017), and mood (P=0.035). At week three there was significant deterioration for visual analogue scale (P=0.047) and mood (P=0.013) in the homoeopathic immunotherapy group compared with the placebo group. Any improvement in participants' asthma was independent of belief in complementary medicine. CONCLUSION: Homoeopathic immunotherapy is not effective in the treatment of patients with asthma. The different patterns of change between homoeopathic immunotherapy and placebo over the course of the study are unexplained.
Asunto(s)
Asma/terapia , Polvo , Homeopatía , Hipersensibilidad Inmediata/terapia , Ácaros , Adulto , Afecto , Animales , Asma/inmunología , Asma/psicología , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado , Humanos , Hipersensibilidad Inmediata/inmunología , Masculino , Persona de Mediana Edad , Calidad de Vida , Pruebas Cutáneas , Factores de Tiempo , Insuficiencia del TratamientoRESUMEN
Cysteinyl-leukotrienes and prostaglandin D2 generated by the 5-lipoxygenase (5-LO) and cyclooxygenase (COX) pathways, respectively, cause bronchoconstriction, leukocyte recruitment, and bronchial hyperresponsiveness in asthma. We characterized the cellular expression of 5-LO and COX enzymes using immunohistochemistry on bronchial biopsies from 12 allergic asthmatic patients before and during seasonal exposure to birch pollen. Bronchial responsiveness (p = 0.004) and symptoms (p < 0.005) increased and peak expiratory flow (PEF; p < or = 0.02) decreased in the pollen season. In-season biopsies had 2-fold more cells immunostaining for 5-LO (p = 0.02), 5-LO-activating protein (FLAP; p = 0.04), and leukotriene (LT)A4 hydrolase (p = 0.05), and 4-fold more for the terminal enzyme for cysteinyl-leukotriene synthesis, LTC4 synthase (p = 0.02). Immunostaining for COX-1, COX-2, and PGD2 synthase was unchanged. Increased staining for LTC4 synthase was due to increased eosinophils (p = 0.035) and an increased proportion of eosinophils expressing the enzyme (p = 0.047). Macrophages also increased (p = 0.019), but mast cells and T-lymphocyte subsets were unchanged. Inverse correlations between PEF and 5-LO(+) cell counts link increased expression of 5-LO pathway enzymes in eosinophils and macrophages within the bronchial mucosa to deterioration of lung function during seasonal allergen exposure.
Asunto(s)
Araquidonato 5-Lipooxigenasa/análisis , Araquidonato 5-Lipooxigenasa/metabolismo , Asma/metabolismo , Asma/patología , Hiperreactividad Bronquial/metabolismo , Hiperreactividad Bronquial/patología , Hipersensibilidad/metabolismo , Hipersensibilidad/patología , Leucotrienos/análisis , Leucotrienos/metabolismo , Polen/efectos adversos , Prostaglandina-Endoperóxido Sintasas/análisis , Prostaglandina-Endoperóxido Sintasas/metabolismo , Prostaglandinas/análisis , Prostaglandinas/metabolismo , Estaciones del Año , Adulto , Contaminación del Aire/efectos adversos , Contaminación del Aire/análisis , Araquidonato 5-Lipooxigenasa/inmunología , Asma/etiología , Asma/fisiopatología , Biopsia , Hiperreactividad Bronquial/etiología , Hiperreactividad Bronquial/fisiopatología , Eosinófilos/inmunología , Volumen Espiratorio Forzado , Humanos , Hipersensibilidad/etiología , Hipersensibilidad/fisiopatología , Inmunohistoquímica , Recuento de Leucocitos , Leucotrienos/inmunología , Macrófagos/inmunología , Mastocitos/inmunología , Ápice del Flujo Espiratorio , Prostaglandina-Endoperóxido Sintasas/inmunología , Prostaglandinas/inmunología , Índice de Severidad de la Enfermedad , Suecia , Linfocitos T/inmunología , ÁrbolesRESUMEN
OBJECTIVE: To evaluate whether electrodermal testing for environmental allergies can distinguish between volunteers who had previously reacted positively on skin prick tests for allergy to house dust mite or cat dander and volunteers who had reacted negatively to both allergens. DESIGN: Double blind, randomised block design. SETTING: A general practice in southern England. PARTICIPANTS: 15 volunteers who had a positive result and 15 volunteers who had a negative result on a previous skin prick test for allergy to house dust mite or cat dander. INTERVENTION: Each participant was tested with 6 items by each of 3 operators of the Vegatest electrodermal testing device in 3 separate sessions (a total of 54 tests per participant). For each participant the 54 items comprised 18 samples each of house dust mite, cat dander, and distilled water, though these were randomly allocated among the operators in each session. A research nurse sat with the participant and operator in all sessions to ensure blinding and adherence to the protocol and to record the outcome of each test. OUTCOME: The presence or absence of an allergy according to the standard protocol for electrodermal testing. RESULTS: All the non-atopic participants completed all 3 testing sessions (810 individual tests); 774 (95.5%) of the individual tests conducted on the atopic participants complied with the testing protocol. The results of the electrodermal tests did not correlate with those of the skin prick tests. Electrodermal testing could not distinguish between atopic and non-atopic participants. No operator of the Vegatest device was better than any other, and no single participant's atopic status was consistently correctly diagnosed. CONCLUSION: Electrodermal testing cannot be used to diagnose environmental allergies.
Asunto(s)
Impedancia Eléctrica , Hipersensibilidad/diagnóstico , Adulto , Anciano , Alérgenos/inmunología , Animales , Gatos , Método Doble Ciego , Electroacupuntura , Humanos , Hipersensibilidad/inmunología , Persona de Mediana Edad , Ácaros , Valor Predictivo de las Pruebas , Pruebas Cutáneas/instrumentación , Pruebas Cutáneas/métodosRESUMEN
Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids represent a management challenge. Leukotrienes play a key role in asthma pathophysiology, and since pro-inflammatory leukotrienes are poorly suppressed by corticosteroids it seems rational to add a leukotriene receptor antagonist (LTRA) when a low to moderate dose of inhaled corticosteroids does not provide sufficient disease control. Long acting beta2-agonist (LABA) treatment represents an alternative to LTRAs and both treatment modalities have been shown to provide additional disease control when added to corticosteroid treatment. To compare the relative clinical benefits of adding either a LTRA or a LABA to asthma patients inadequately controlled by inhaled corticosteroids, a randomized, double-blind, multi-centre, 48-week study will be initiated at approximately 120 centres throughout Europe, Latin America, Middle East, Africa and the Asia-Pacific region in early 2000. The study will compare the oral LTRA montelukast with the inhaled LABA salmeterol, each administered on a background of inhaled fluticasone, on asthma attacks, quality of life, lung function, eosinophil levels, healthcare utilization, and safety, in approximately 1200 adult asthmatic patients. The requirements for study enrollment include a history of asthma, FEV1 or PEFR values between 50% and 90% of the predicted value together with > or = 12% improvement in FEV1 after beta-agonist administration, a minimum pre-determined level of asthma symptoms and daily beta-agonist medication. The study will include a 4-week run-in period, during which patients previously taking inhaled corticosteroids are switched to open-label fluticasone (200 microg daily), followed by a 48-week double-blind, treatment period in which patients continuing to experience abnormal pulmonary function and daytime symptoms are randomized to receive montelukast (10 mg once daily) and salmeterol placebo, or inhaled salmeterol (100 microg daily) and montelukast placebo. All patients will continue with inhaled fluticasone (200 microg daily). During the study, asthma attacks, overnight asthma symptoms, and morning peak expiratory flow rate will be assessed using patient diary cards; quality of life will also be assessed using an asthma-specific quality-of life questionnaire. The results of this study are expected to provide physicians with important clinical evidence to help them make a rational and logical treatment choice for asthmatic patients experiencing breakthrough symptoms on inhaled corticosteroids.
Asunto(s)
Acetatos/administración & dosificación , Corticoesteroides/administración & dosificación , Androstadienos/uso terapéutico , Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Antagonistas de Leucotrieno/administración & dosificación , Quinolinas/administración & dosificación , Administración por Inhalación , Adolescente , Adulto , Anciano , Albuterol/administración & dosificación , Asma/fisiopatología , Ciclopropanos , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Persona de Mediana Edad , Ápice del Flujo Espiratorio/efectos de los fármacos , Calidad de Vida , Quinolonas/administración & dosificación , Sulfuros , Encuestas y CuestionariosRESUMEN
Immunoglobulin E (IgE) mediates its effector functions via the Fc region of the molecule. IgE binding to and subsequent aggregation of the high-affinity receptor (Fc epsilon RI) by allergen plays a pivotal role in type I hypersensitivity responses. Earlier studies implicated the C epsilon 2 and 3 interface and the A-B loop in C epsilon 3 in the IgE-Fc epsilon RI interaction. These regions and glycosylation sites in C epsilon 3 were now targeted by site-specific mutagenesis. IgE binding to Fc epsilon RI was compared with surface plasmon resonance (SPR) measurements, which assessed the binding of the soluble extracellular domain of Fc epsilon RI to IgE. Kinetic analysis based on a pseudo-first-order model agrees with previous determinations. A more refined SPR-based kinetic analysis suggests a biphasic interaction. A model-free empirical analysis, comparing the binding strength and kinetics of native and mutant forms of IgE, identified changes in the kinetics of IgE-Fc epsilon RI interaction. Conservative substitutions introduced into the A-B loop have a small effect on binding, suggesting that the overall conformation of the loop is important for the complementary interaction, but multiple sites across the C epsilon 3 domain may influence IgE-Fc epsilon RI interactions. Asn394 is essential for the generation of a functional IgE molecule in mammalian cells. A role of Pro333 in the maintenance of a constrained conformation at the interface between C epsilon 2-3 emerged by studying the functional consequences of replacing this residue by Ala and Gly. These substitutions cause a dramatic decrease in the ability of the ligand to mediate stimulus secretion coupling, although only small changes in the association and dissociation rates are observed. Understanding the molecular basis of this phenomenon may provide important information for the design of inhibitors of mast cell degranulation.
Asunto(s)
Aminoácidos/fisiología , Inmunoglobulina E/fisiología , Receptores de IgE/fisiología , Animales , Vectores Genéticos , Humanos , Inmunoglobulina E/genética , Inmunoglobulina E/metabolismo , Cinética , Leucemia Basofílica Aguda , Ligandos , Modelos Moleculares , Mutagénesis Sitio-Dirigida , Pichia/genética , Ingeniería de Proteínas , Ratas , Agregación de Receptores , Receptores de IgE/genética , Receptores de IgE/metabolismo , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/síntesis química , Proteínas Recombinantes/metabolismo , Solubilidad , Células Tumorales CultivadasRESUMEN
BACKGROUND: Bronchial challenge with allergen causes a specific form of airways inflammation consisting of an influx of neutrophils, eosinophils, and T cells. Because the relevance of the challenge model to clinical asthma is uncertain, the cellular changes that occur in the lungs of asthmatic subjects during natural seasonal allergen exposure were investigated. METHODS: Seventeen grass pollen sensitive asthmatic subjects with previously reported seasonal exacerbations of asthma kept records of symptoms and underwent fibreoptic bronchoscopy with bronchoalveolar lavage (BAL) and endobronchial biopsy before and during the peak of the grass pollen season. The BAL cells were analysed for differential cell counts and by flow cytometry for T cell subsets and surface activation markers. The biopsy samples were processed into glycol methacrylate resin and immunohistochemical analysis was performed for mast cells, activated eosinophils, T cells and interleukin 4 (IL-4), a cytokine with a pivotal role in allergen-induced inflammation. RESULTS: In the pollen season there was an increase in T lymphocyte activation in the BAL fluid as identified by increased expression of interleukin 2 receptor (IL-2R). In the submucosa these changes were paralleled by an increase in CD4+ T cells. By contrast, the numbers of metachromatic cells in BAL fluid staining with toluidine blue were reduced, possibly because of degranulation following allergen stimulation. In keeping with mast cell activation, the number of mucosal mast cells staining for secreted IL-4 increased during the season. In comparison with the period shortly before the onset of the season, all but two subjects experienced an asthma exacerbation which followed the rise in pollen counts but, compared with the period preceding the first bronchoscopic examination, asthma symptoms were not increased during the pollen season. CONCLUSIONS: The data suggest that natural allergen exposure, leading to a clinical exacerbation of asthma, may induce an inflammatory response involving T cells, mast cells and eosinophils. The relationship between allergen exposure, cellular infiltration and activation, and clinical symptoms appears to be complex, with factors other than allergen also contributing to asthmatic activity.
Asunto(s)
Alérgenos/inmunología , Asma/inmunología , Pulmón/inmunología , Polen/inmunología , Rinitis Alérgica Estacional/inmunología , Adulto , Bronquios/inmunología , Líquido del Lavado Bronquioalveolar/inmunología , Eosinófilos/inmunología , Femenino , Humanos , Activación de Linfocitos , Masculino , Mastocitos/inmunología , Persona de Mediana Edad , Subgrupos de Linfocitos T/inmunologíaRESUMEN
The role of the thromboxane A2 (TxA2) receptor in bradykinin-induced bronchial responses was investigated in this study by using a selective and potent TxA2-receptor antagonist BAY u 3405. Eleven asthmatic subjects were randomized to receive 50 mg of BAY u 3405 or matched placebo in a crossover and double-blind fashion. Ninety minutes after dosing, serum was taken for drug assay, and subjects underwent provocation with bradykinin or prostaglandin D2 (PGD2) to determine bronchial responsiveness [provocative concentration of agonist required to produce a 20% fall in forced expiratory volume in 1 s from the postdiluent baseline (PC20)]. Pretreatment with BAY u 3405 caused a twofold doubling-dilution reduction in bronchial reactivity to PGD2; the geometric mean PC20 values were 0.132 (0.015-0.871) and 0.034 (0.008-0.095) mg/ml, respectively, for active and placebo days (P = 0.001). There was, however, no significant difference in PC20 values for bradykinin between active and placebo treatment days. We have demonstrated that BAY u 3405 caused a significant inhibition of bronchconstriction induced by inhaled PGD2 but had no influence on bronchial responsiveness to inhaled bradykinin. This study suggests therefore that TxA2 receptors do not play a role in bradykinin-induced bronchoconstriction in asthma.
Asunto(s)
Asma/tratamiento farmacológico , Bradiquinina/farmacología , Broncoconstricción/efectos de los fármacos , Carbazoles/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Receptores de Tromboxanos/antagonistas & inhibidores , Sulfonamidas/uso terapéutico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Local hyperthermia reduces mast cell degranulation, the severity of acute lung injury, and exercise-induced asthma and decreases symptoms of rhinitis. We have investigated the effect of local hyperthermia on mast cell degranulation and symptom generation in allergic rhinitis to assess its effect and mechanism of action within the nose. METHODS: In a randomized, double-blind, placebo-controlled, crossover study, 10 subjects with rhinitis were treated for 30 minutes with local hyperthermia or placebo, which was followed 30 minutes later by nasal allergen challenge. During the first two visits nasal lavages were performed to assess vascular leakage and mediator release. During the last two visits nasal airway resistance, the number of sneezes, and mucus secretion were monitored. RESULTS: Local hyperthermia significantly reduced both nasal airway resistance (p < 0.05) and vascular leakage (p < 0.02) but had no significant effect on the number of sneezes, on mucus secretion, or on tryptase release. CONCLUSION: Local hyperthermia reduces allergen-provoked nasal blockage and vascular leakage but has no effect on sneezing, rhinorrhea, or tryptase release. Nasal blockage occurs predominantly via newly formed lipid mediators and kinins, whereas sneezing and rhinorrhea occur predominantly via preformed mediators. We propose that local hyperthermia inhibits newly formed mediator production or release or reduces the sensitivity of the vasculature to inflammatory mediators in general. Further investigation into the mechanisms and potential uses of local hyperthermia is warranted.
Asunto(s)
Hipertermia Inducida , Mucosa Nasal/fisiopatología , Rinitis Alérgica Estacional/terapia , Adulto , Resistencia de las Vías Respiratorias , Permeabilidad Capilar , Quimasas , Método Doble Ciego , Femenino , Humanos , Masculino , Mastocitos/enzimología , Mucosa Nasal/irrigación sanguínea , Mucosa Nasal/inmunología , Pruebas de Provocación Nasal , Rinitis Alérgica Estacional/inmunología , Rinitis Alérgica Estacional/fisiopatología , Serina Endopeptidasas/análisis , TriptasasRESUMEN
We developed a model of asthma in conscious guinea pigs in which both early- and late-phase reductions in specific airways conductance are demonstrable after inhalation challenge. Neutrophilia that peaks 17 hours after challenge was discovered by bronchoalveolar lavage in this model, as was eosinophilia that develops more slowly, peaking at 72 hours. Nedocromil sodium blocked both the early- and late-phase reductions in airflow, but salbutamol blocked only the early phase. Both drugs blocked the neutrophilia when given before challenge, but not when given 6 hours afterward. This suggests that the neutrophila is secondary to an intact early phase response. Nedocromil sodium, given 6 hours after challenge, reduced the eosinophilia at 72 hours but not at 17 hours. Salbutamol had no effect on the eosinophilia at either time. These results suggest that nedocromil sodium has antiinflammatory properties in the lung that are not shared by the beta 2-adrenergic stimulant drug, salbutamol.
Asunto(s)
Alérgenos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Asma/tratamiento farmacológico , Modelos Animales de Enfermedad , Quinolonas/uso terapéutico , Aerosoles , Albuterol/uso terapéutico , Animales , Asma/etiología , Líquido del Lavado Bronquioalveolar/citología , Depresión Química , Evaluación Preclínica de Medicamentos , Eosinófilos/efectos de los fármacos , Cobayas , Nedocromil , Neutrófilos/efectos de los fármacos , Factores de TiempoRESUMEN
1. The potent bronchoconstrictors prostaglandin (PG) D2, PG F2 alpha and thromboxane A2 are thought to have a role in the pathogenesis of asthma, mediated via the thromboxane (TP) receptor. 2. BAY u 3405 is a new potent selective competitive TP receptor antagonist. 3. The effect of single oral doses of 20 mg and 50 mg BAY u 3405 was examined against histamine and PG D2 bronchial provocation at 90 min after drug ingestion and, for the 20 mg dose alone, at 60 min after ingestion, in randomised, double-blind placebo controlled crossover studies. A time course study was performed with the 20 mg dose. 4. BAY u 3405 protected against PG D2 bronchial provocation. The 20 mg dose increased the amount of PG D2 required to produce a fall of 20% in the forced expiratory volume in 1 s by 6-fold and 16-fold at 60 min and 90 min after ingestion respectively, and the 50 mg dose by 14-fold at 90 min after ingestion. 5. The specificity of the drug was confirmed in vivo in that there was no significant protection against histamine bronchial provocation at either dose or at either time point. 6. The time course study showed significant protection against PG D2 bronchial provocation at 1 h and at 3 h after a single 20 mg oral dose. 7. There was no correlation between subjects in plasma BAY u 3405 concentration and drug effect. Within the subjects performing the time course study there was a strong correlation in time between drug effect and plasma BAY u 3405 concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Asma/tratamiento farmacológico , Broncoconstricción/efectos de los fármacos , Carbazoles/uso terapéutico , Antagonistas de los Receptores Histamínicos/farmacología , Prostaglandina D2/antagonistas & inhibidores , Sulfonamidas/uso terapéutico , Tromboxanos/antagonistas & inhibidores , Adulto , Asma/fisiopatología , Pruebas de Provocación Bronquial , Carbazoles/farmacocinética , Carbazoles/farmacología , Femenino , Histamina/farmacología , Humanos , Masculino , Persona de Mediana Edad , Prostaglandina D2/farmacología , Pruebas de Función Respiratoria , Sulfonamidas/farmacocinética , Sulfonamidas/farmacologíaRESUMEN
BACKGROUND: Prior treatment with local hyperthermia has been shown to prevent mast cell degranulation and leucocyte histamine release, and to reduce mortality and cellular infiltrates in a model of acute lung injury. Local hyperthermia is effective in reducing the symptoms of the common cold and perennial and seasonal allergic rhinitis, nasal patency also being improved in rhinitis. It is possible that these effects are mediated by common anti-inflammatory mechanisms, and that this treatment may be effective in the treatment of asthma. The effect of prior local hyperthermia on the response to exercise challenge and histamine bronchoprovocation was therefore examined. METHODS: In a randomised, double blind, placebo controlled, crossover study, 10 asthmatic subjects with exercise induced asthma used machines delivering 40 1/minute of fully humidified air at either 42 degrees C (active treatment) or 31 degrees C (placebo treatment) for 30 minutes' tidal breathing. For each pretreatment, at two week intervals they underwent exercise challenges starting one and 24 hours after starting the inhalations. After a further two weeks the protocol was repeated with histamine substituted for the exercise challenges. RESULTS: The mean (SE) maximum percentage fall in forced expiratory volume in one second (FEV1) was significantly lower one hour after treatment with air at 42 degrees C (30.8% (3.1%)) than after treatment with air at 31 degrees C (22.3% (2.9%)). There was no significant effect on exercise challenge at 24 hours, or on histamine challenge at either time point, though there were nonsignificant trends towards protection with exercise at 24 hours and with histamine at one hour. CONCLUSION: In asthmatic subjects the response to exercise challenge is significantly attenuated one hour after treatment with local hyperthermia. This treatment warrants further investigation in the treatment of clinical asthma and other inflammatory disorders.
Asunto(s)
Asma Inducida por Ejercicio/terapia , Hipertermia Inducida/instrumentación , Adolescente , Adulto , Asma Inducida por Ejercicio/fisiopatología , Prueba de Esfuerzo , Femenino , Volumen Espiratorio Forzado , Humanos , Pulmón/fisiopatología , Masculino , Persona de Mediana EdadRESUMEN
1. We have assessed the effect of a specific histamine H1-receptor antagonist, terfenadine, in the treatment of atopic asthmatics during the grass pollen season. 2. Eighteen mild, grass pollen sensitive asthmatics (10F, 8M, mean +/- s.e. mean age 34.7 +/- 5.6 years), all of whom were controlled on inhaled beta 2-adrenoceptor agonists alone, took part in a 9 week, double-blind, crossover study using terfenadine 180 mg three times daily and placebo. Throughout the study patients recorded peak expiratory flow rate (PEFR) twice daily, symptoms of cough, wheeze, breathlessness and chest tightness (scored 0-3), and their use of bronchodilators. Methacholine inhalation challenge tests were performed each week. Data were analysed by a method suitable for a two group, two period crossover trial with baseline measurements. 3. Terfenadine significantly reduced symptoms of cough by 76.9% (P less than 0.05) and wheeze by 46.9% (P less than 0.02). Symptoms of breathlessness and chest tightness were reduced by 16.8 and 30.3% respectively but these were not statistically significant. Morning and evening PEFR rose by 5.5 (P less than 0.001) and 6.2% (P less than 0.003) respectively on treatment with terfenadine and bronchodilator use fell by 40.3%. A progressive increase in methacholine sensitivity was seen in both treatment groups throughout the study but did not reach statistical significance. 4. We conclude that treatment with terfenadine during the grass pollen season in sensitive asthmatics reduced their symptoms and bronchodilator requirements and produced a modest improvement in their lung function without affecting the development of increased methacholine sensitivity that occurred during the grass pollen season.
Asunto(s)
Asma/tratamiento farmacológico , Compuestos de Bencidrilo/uso terapéutico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Polen/inmunología , Adulto , Asma/inmunología , Método Doble Ciego , Femenino , Humanos , Masculino , Estadística como Asunto , TerfenadinaRESUMEN
1. Selenium is an essential component of glutathione peroxidase (GSH-Px, EC 1.11.1.9), an enzyme which helps protects cells against damage caused by free radicals and hydroperoxides. 2. We report the plasma, whole blood and platelet concentrations of selenium, and whole blood and platelet activities of GSH-Px, in 49 patients with asthma, 23 of whom had coexisting eczema, and 76 healthy control subjects. 3. The asthmatic patients had significantly lower concentrations of selenium measured in plasma (P less than 0.001) and whole blood (P less than 0.001), but not in platelets. When the data were summarized as odds ratios there was a highly significant 3.54- and 5.08-fold increased probability of asthma observed for the lower range of plasma and whole blood selenium concentrations, respectively. 4. No overall decrease in platelet or whole blood GSH-Px activity was found when the asthmatic and control groups were compared. 5. Although patients with symptomatic asthma have a reduced selenium status, this does not appear to influence the antioxidant capacity of their circulating blood cells.
Asunto(s)
Asma/sangre , Selenio/sangre , Adolescente , Adulto , Asma/enzimología , Plaquetas/análisis , Femenino , Glutatión Peroxidasa/sangre , Humanos , Masculino , Persona de Mediana EdadRESUMEN
We have examined the effect of azelastine, a new H1 histamine receptor antagonist, against bronchoconstriction induced by histamine and allergen. Twelve mild, atopic asthmatics each underwent two histamine and two allergen concentration-response inhalation challenges 4 hr after treatment with either 8.8 mg of azelastine or a matched placebo. Following azelastine the dose of histamine required to provoke a 20% fall in FEV1 (PD20 histamine) rose, from a geometric mean of 0.31 mg/ml to greater than 13.2 mg/ml. Azelastine also significantly inhibited allergen-induced bronchoconstriction, the PD20 allergen rising from 9.3 cumulative breath units (c.b.u.) to greater than 47.9 c.b.u., a greater than 5-fold increase. We conclude that azelastine effectively inhibits both histamine and allergen-induced bronchoconstriction, with considerably greater potency against histamine.
Asunto(s)
Asma/tratamiento farmacológico , Bronquios/efectos de los fármacos , Ftalazinas/farmacología , Piridazinas/farmacología , Administración por Inhalación , Administración Oral , Adulto , Método Doble Ciego , Volumen Espiratorio Forzado , Histamina/farmacología , Humanos , Polen , Distribución Aleatoria , Factores de TiempoRESUMEN
In 47 atopic subjects, skin-prick testing to 10 common allergens was performed, and specific IgE to the same allergens was assessed by the multi-allergosorbent chemiluminescent assay (MAST-CLA). Overall agreement between the tests was 66.4% for conventionally positive skin tests (weal diameter greater than or equal to 3 mm), rising to 78.5% when a positive skin test was defined as having a weal diameter greater than or equal to 5 mm. Agreement between the tests was statistically significant for all allergens except Alternaria. A history was obtained from each subject of the presence or absence of allergic symptoms on exposure to cats, and whether there was a history of grass pollen allergy. MAST-CLA testing for specific IgE to cat dander predicted a history of cat allergy with an efficiency of 74.5%, while a positive MAST-CLA test for Cocksfoot grass predicted a history of grass pollen allergy with an efficiency of 85.1%. Similar results were obtained on skin testing for these allergens. We conclude that MAST-CLA gave results comparable to those obtained by skin-prick testing, and correlated equally well with the history of allergic symptoms.
Asunto(s)
Alérgenos , Hipersensibilidad Inmediata/diagnóstico , Técnicas de Inmunoadsorción , Pruebas Cutáneas , Adulto , Animales , Gatos , Femenino , Cabello , Humanos , Inmunoglobulina E/análisis , Mediciones Luminiscentes , Masculino , Poaceae , PolenRESUMEN
The pollen of Parietaria species is a well-recognized and important inhalant allergen in the Mediterranean area. Parietaria judaica (Pellitory-of-the-Wall) is native to the U.K., flowering from June to September, but is not usually considered to be of any clinical importance by U.K. allergists. We skin tested 62 patients with a clinical history of summer seasonal respiratory symptoms and a control group of 11 patients with perennial respiratory symptoms only. Each was skin tested in duplicate with extracts of grass pollen, birch pollen, Parietaria pollen, Dermatophagoides pteronyssinus, Cladosporium, Alternaria, nettle pollen and negative and positive controls, and serum samples were collected for RAST assays for Parietaria and nettle. Eight of the 62 patients in the main group showed skin reactivity to Parietaria. Five of these eight had never visited the Mediterranean area and therefore it is possible that sensitization occurred in the U.K. Thirteen of the 62 patients were skin reactive to nettle but there was no correlation between skin reactivity to Parietaria and nettle. This supports a recent report that, despite their close botanical relationship, no antigenic cross-reactivity exists between the two species. No correlation was seen between skin reactivity and serum RAST activity to Parietaria or nettle. It is not known whether exposure to Parietaria pollen contributes to the seasonal symptoms of the patients found to be skin reactive. None of the 11 patients in the control group was skin reactive to Parietaria.
Asunto(s)
Hipersensibilidad/etiología , Polen/inmunología , Adolescente , Adulto , Inglaterra , Humanos , Pruebas CutáneasRESUMEN
1. The effect of three single doses of nifedipine on exercise-induced asthma has been examined in 11 asthmatic subjects. 2. On four separate days patients undertook 6 min of exercise on a treadmill 30 min after taking placebo or nifedipine 10, 20 or 30 mg administered double-blind and in random order. 3. Nifedipine had no significant effect on resting FEV1 measurements. 4. Nifedipine, in doses of 10, 20 and 30 mg, inhibited exercise induced bronchoconstriction, reducing the maximum fall in FEV1 from 30.8 +/- 3.5% after placebo to 21.9 +/- 3.4% (NS), 13 +/- 3.4% (P less than 0.01) and 15 +/- 3.9% (P less than 0.01) respectively. 5. This study has shown that the protective effect of nifedipine against exercise-induced asthma is dose related with the maximum inhibitory effect being observed with a single dose of 20 mg.
Asunto(s)
Asma Inducida por Ejercicio/tratamiento farmacológico , Asma/tratamiento farmacológico , Nifedipino/uso terapéutico , Adulto , Asma Inducida por Ejercicio/fisiopatología , Relación Dosis-Respuesta a Droga , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , Nifedipino/efectos adversosRESUMEN
Studies in both animals and man suggest a role for cholinergically-mediated reflex bronchoconstriction in the airflow limitation of asthma. Muscarinic cholinergic antagonists such as atropine, ipratropium bromide (IB) and oxitropium bromide (OB) when delivered locally to the airways are bronchodilators and antibronchoconstrictors. Although drugs like IB and OB offer advantages over some of the older anticholinergic preparations in terms of pharmacokinetics and therapeutic ratio, they cannot be considered as first line drugs in the therapy of acute asthma. However, when used in combination with other anti-asthma drugs, therapeutic benefit of inhaled IB and OB is obtained by maximising the bronchodilator properties of the individual drugs without attendant systemic side effects. Finally, the removal of the preservatives EDTA and benzylchonium chloride from Atrovent nebulizer solution has removed the risk of paradoxical bronchoconstriction occurring.
Asunto(s)
Asma/tratamiento farmacológico , Parasimpatolíticos/uso terapéutico , Enfermedad Aguda , Administración por Inhalación , Animales , Pruebas de Provocación Bronquial , Quimioterapia Combinada , Humanos , Ipratropio/uso terapéutico , Derivados de Escopolamina/uso terapéuticoRESUMEN
Human cutaneous mast cells show functional differences from their counterparts in other tissues. Following passive sensitization with 1% atopic serum for 30 min at 37 degrees C human skin slices released histamine after challenge with anti-human IgE in a concentration dependent manner. Maximum release of 14 +/- 2% was achieved with a 1/10 dilution of anti-IgE. Passive sensitization with 10% atopic serum increased the secretory response to anti-IgE but histamine release was only concentration related over the entire 1/1000 to 1/10 dilution range in half of the specimens studied, the remainder showing high dose tolerance to anti-IgE. Negligible histamine release occurred with anti-IgE challenge of slices which had not been passively sensitized. The histamine releasing ability of A23187 in human skin slices was similar to that observed in lung and adenoidal mast cells being concentration dependent over the range 0.1-3 microM with a maximum release of 25 +/- 3%. In contrast to human lung and adenoidal mast cells, poly-L-lysine and compound 48/80 induced histamine release from skin slices. Poly-L-lysine induced a concentration-dependent release of histamine over the range 0.01-10 microM with a maximum of 27 +/- 3%. The response to compound 48/80 was variable, releasing in some but not all specimens. Histamine release caused by anti-IgE, A23187 and poly-L-lysine was shown to be dependent upon extracellular calcium while release stimulated by compound 48/80 was calcium independent. The chemotactic peptide, formyl-methionyl-leucyl-phenylalanine, over the range 0.01-10 microM failed to release histamine from skin slices.(ABSTRACT TRUNCATED AT 250 WORDS)